|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy.
|
30382507 |
2019 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathologically, FTLD presents with tauopathy or TAR DNA-binding protein 43 (TDP-43) proteinopathy.
|
29807909 |
2018 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
We interrogated pathological Alzheimer's disease (n = 247); other tauopathies (n = 95) including Pick's disease, corticobasal disease and progressive supranuclear palsy; the synucleinopathies (n = 164) including multiple system atrophy and Lewy body disease; the TDP-43 proteinopathies (n = 188) including frontotemporal lobar degeneration with TDP-43 inclusions and amyotrophic lateral sclerosis; and a minimal pathology group (n = 72).
|
29878075 |
2018 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy.
|
28550263 |
2017 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies.
|
28487370 |
2017 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that TDP-43 could be a putative target for therapeutic intervention in AD affecting both Aβ plaque formation and tauopathy.
|
28416393 |
2017 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
In this prion-centric view, FTD can be divided into three subtypes, TDP-43 or FUS proteinopathy and tauopathy.
|
27502124 |
2016 |
|
Tauopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We therefore investigated 33 patients with FTLD-tau (including 9 with MAPT mutation) for TDP-43 pathological changes, and 45 patients with FTLD-TDP (including 12 with hexanucleotide expansion in C9ORF72 and 12 with GRN mutation), and 23 patients with motor neurone disease (3 with hexanucleotide expansion in C9ORF72), for tauopathy.
|
24861427 |
2014 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
We performed immunohistochemical staining to clarify the localization of SIGMAR1 in the brains of patients with neurodegenerative disorders, including trans-activation response DNA protein 43 (TDP-43) proteinopathy, tauopathy, α-synucleinopathy, polyglutamine disease and intranuclear inclusion body disease (INIBD).
|
24313828 |
2014 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
These data demonstrate that the neurodegenerative cascade associated with a primary tauopathy in tau transgenic mice can also promote TDP-43 abnormalities.
|
23666556 |
2013 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Biofluid studies identify about 15% of patients with FTLD due to a genetic mutation that is associated with the specific histopathologic features of TDP-43 or a tauopathy.
|
21833654 |
2011 |
|
Tauopathies
|
0.100 |
Biomarker
|
group |
BEFREE |
Biofluid studies identify about 15% of patients with FTLD due to a genetic mutation that is associated with the specific histopathologic features of TDP-43 or a tauopathy.
|
20881489 |
2010 |
|
Tauopathies
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Many of the familial FTLDs are linked to chromosome 17, including both the familial tauopathies and the familial TAR DNA-binding protein-43 proteinopathies with progranulin mutations.
|
18596549 |
2008 |